NASDAQ:EIDX - Eidos Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $21.40 -0.10 (-0.47 %) (As of 07/18/2018 12:43 PM ET)Previous Close$21.20Today's Range$20.80 - $21.4052-Week Range$18.10 - $24.75Volume735 shsAverage Volume326,611 shsMarket Capitalization$781.10 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsInsider TradesHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email There is no company description available for Eidos Therapeutics Inc. Receive EIDX News and Ratings via Email Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:EIDX CUSIPN/A Webwww.eidostx.com Phone415-887-1471 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees14 Outstanding Shares35,810,000Market Cap$781.10 Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions What is Eidos Therapeutics' stock symbol? Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX." What price target have analysts set for EIDX? 3 analysts have issued 1 year price objectives for Eidos Therapeutics' stock. Their predictions range from $24.00 to $36.00. On average, they anticipate Eidos Therapeutics' share price to reach $30.6667 in the next year. This suggests a possible upside of 44.7% from the stock's current price. View Analyst Ratings for Eidos Therapeutics. What is the consensus analysts' recommendation for Eidos Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Eidos Therapeutics' key competitors? Some companies that are related to Eidos Therapeutics include The Medicines (MDCO), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Supernus Pharmaceuticals (SUPN), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI) and Endo International (ENDP). When did Eidos Therapeutics IPO? (EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager. When does Eidos Therapeutics' quiet period expire? Eidos Therapeutics' quiet period expires on Monday, July 30th. Eidos Therapeutics had issued 6,250,000 shares in its IPO on June 20th. The total size of the offering was $106,250,000 based on an initial share price of $17.00. During Eidos Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. Has Eidos Therapeutics been receiving favorable news coverage? News headlines about EIDX stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eidos Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the company an impact score of 45.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. How do I buy shares of Eidos Therapeutics? Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eidos Therapeutics' stock price today? One share of EIDX stock can currently be purchased for approximately $21.20. How big of a company is Eidos Therapeutics? Eidos Therapeutics has a market capitalization of $781.10 million. Eidos Therapeutics employs 14 workers across the globe. How can I contact Eidos Therapeutics? Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected] MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 6 (Vote Outperform)Underperform Votes: 7 (Vote Underperform)Total Votes: 13MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?